This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early
Alzheimer's Disease.

Changes in cognitive functions are commonly seen in healthy aging. These changes are usually benign as they will not seriously hinder the ability to perform activities of daily living. However, older adults have a higher risk of developing cognitive impairments. A prevalent condition that affect cognitive functions in older adults is Alzheimer's disease.

By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen
in the body, causes an increase in mitochondrial activity. Researchers also hope to
determine the safety and tolerability of a therapeutic dose of S-equol and whether or not it
influences cognition.

This clinical trial will test the FamTechCare intervention that uses multidisciplinary
professional guidance based on in-home video monitoring to support family caregivers in
managing challenging behaviors of persons with dementia (PWD). Families provide the majority
of care for PWD at home. However the stress of caregiving is so significant that it
increases caregiver morbidity and mortality. Stress is magnified by disruptive behaviors in
PWD that frequently lead to nursing home placement. In-home video monitoring allows experts
to assess behaviors of PWD and to identify antecedents, recommend specific interventions.
FamTechCare uses new technology to link family caregivers to experts for guidance in
managing disruptive behaviors, supporting continued care at home while reducing the negative
effects of caregiving.

Caregiver-PWD dyads (N=88) will be randomly assigned to intervention or control groups. Both
groups will record behaviors during daily care for 3 months using a home monitoring unit.
Notably, this new technology captures 3-5 minutes prior to the behavior, thus recording
behavior triggers and precursors. Caregivers record care situations they select and upload
videos to a secure site. The expert team will review intervention group videos weekly and
will provide individualized feedback for improving care to caregivers in the home. The
control group caregivers will receive a weekly phone call and advice from a nurse, but their
recorded videos will be held for review and individualized feedback provided after 3 months.

Study aims are to use observation to assist caregivers in behavior management. Effects on
disruptive behaviors and caregiver burden and other negative outcomes will be compared.
Investigators will evaluate ease of use and satisfaction, cost-efficiency, and factors
influencing likelihood of translation into practice. This is the first study to test new
technology for direct observation and immediate feedback to empower families to manage PWD
behaviors at home while reducing caregiver stress and morbidity. Technology links caregivers
to individualized expert guidance, acknowledging the importance and burden of their role.
This study addresses NIH missions and the 2012 National Plan to Address Alzheimer's disease
goals, integrating strategies to promote adoption and use of aging services technologies in
interventions that will reduce negative caregiver outcomes, a growing public health problem.

The purpose of the Alzheimer's Prevention Registry GeneMatch program is to identify a large
group of people interested in participating in research studies or clinical trials based in
part on their genetic background. This genetic information will be used to match interested
individuals to studies, providing a recruitment resource to the Alzheimer's scientific
community. Interested individuals should visit www.endALZnow.org/GeneMatch to join the
GeneMatch program.

By doing this study, researchers hope to learn if older adults with and without cognitive
impairment can adhere to a Mediterranean diet.

Physical inactivity, high blood pressure and dyslipidemia are risk factors for Alzheimer's
disease (AD) and vascular dementia. Importantly, these risk factors are modifiable with
lifestyle changes, pharmacological treatment, or both. The rrAD study will determine effects
of aerobic exercise training and intensive vascular risk reduction on cognitive performance
in older adults who have high risk for AD.

The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at
doses of up to 2 grams per day in people with Alzheimer's disease (AD).

Study objective: This study aims to examine the effects of aerobic exercise in individuals at high risk for Alzheimer's disease, as determined by an amyloid brain imaging scan. This study will observe whether 52 weeks of aerobic exercise is associated with a decrease in amyloid levels in the brain, as measured by the amyloid brain imaging scan.